ITB-Med Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
42
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$140M
- Investors
-
3
ITB-Med General Information
Description
Developer of an immunomodulatory biologic designed for transplantation, autoimmunity, neurodegenerative diseases, and gene therapy. The company's monoclonal antibody allows the complete discontinuation of all immunosuppression treatments, enabling medical practitioners to provide immunosuppression freedom to their patients, potentially leading to better outcomes, improved quality of life, and reduced healthcare costs.
Contact Information
Website
www.itb-med.comCorporate Office
- 110 East 59th Street
- Floor 28
- New York, NY 10022
- United States
Corporate Office
- 110 East 59th Street
- Floor 28
- New York, NY 10022
- United States
ITB-Med Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC | 01-Oct-2022 | $140M | Completed | Generating Revenue | ||
| 1. Early Stage VC | 03-Apr-2018 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ITB-Med Patents
ITB-Med Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026175970-A1 | Anti-cd2 antibody treatment in kidney transplantation | Pending | 19-Feb-2025 | ||
| US-20240285756-A1 | Method and composition for inducing tolerance | Inactive | 07-Sep-2021 | ||
| US-20240101671-A1 | Method and composition for inducing tolerance | Pending | 25-Jan-2021 | ||
| US-20230365687-A1 | Anti-cd2 antibodies | Active | 23-Jun-2020 | ||
| US-12661399-B2 | Method of treating an immune-related disorder or disease associated with an organ or tissue transplant with a combination of an anti-cd2 antibody and a ctla-4 co-stimulation blockade | Active | 23-Jun-2020 | A61K39/3955 |
ITB-Med Signals
ITB-Med Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| GG 1978 | Venture Capital | Minority | ||
| Yaya Capital | Venture Capital | Minority | ||
| Angel (individual) | Minority |
ITB-Med FAQs
-
When was ITB-Med founded?
ITB-Med was founded in 2016.
-
Where is ITB-Med headquartered?
ITB-Med is headquartered in New York, NY.
-
What is the size of ITB-Med?
ITB-Med has 42 total employees.
-
What industry is ITB-Med in?
ITB-Med’s primary industry is Biotechnology.
-
Is ITB-Med a private or public company?
ITB-Med is a Private company.
-
What is ITB-Med’s current revenue?
The current revenue for ITB-Med is .
-
How much funding has ITB-Med raised over time?
ITB-Med has raised $207M.
-
Who are ITB-Med’s investors?
GG 1978, Yaya Capital, and have invested in ITB-Med.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process